Skip to main content
D&D Pharmatech Inc. logo

D&D Pharmatech Inc. — Investor Relations & Filings

Ticker · 347850 ISIN · KR7347850000 KO Manufacturing
Open in API
Filings indexed 109 across all filing types
Latest filing 2024-08-08 Major Shareholding Noti…
Country KR South Korea
Listing KO 347850

About D&D Pharmatech Inc.

http://www.ddpharmatech.com/

D&D Pharmatech is a clinical-stage biopharmaceutical company specializing in the development of therapies based on GLP-1 (Glucagon-like peptide-1) and related peptides. The company's pipeline primarily targets metabolic diseases, including obesity and MASH (Metabolic dysfunction-associated steatohepatitis), as well as neurodegenerative disorders. A core competency is its proprietary oral peptide delivery technology. Key candidates in its portfolio include DD01, an injectable dual GLP-1/glucagon receptor agonist for MASH that has received FDA Fast Track Designation, and an oral GLP-1 therapy for obesity. The company operates a global model, funding drug development through specialized subsidiaries, with research functions in Korea and clinical development managed by its US-based team.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea (often referred to as a 5% rule filing). It details changes in share ownership by Smilegate Investment and its related funds in D&D Pharmatech. This falls under the category of Major Shareholding Notification.
2024-08-08 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 1% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to directors and employees, including exercise prices, vesting periods, and valuation models. Since this is a specific regulatory disclosure regarding capital structure and equity-based compensation that does not fit into other categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for general capital changes), it is classified as a Regulatory Filing.
2024-07-11 Korean
회사합병결정(종속회사의주요경영사항)
M&A Activity Classification · 1% confidence The document is a formal announcement regarding a corporate merger (회사합병 결정) between two subsidiaries of the company D&D Pharmatech. It details the merger method, purpose, and financial impact of the transaction. This falls under M&A activity, which is classified as 'TAR'.
2024-07-01 Korean
투자판단관련주요경영사항(임상시험계획승인신청등결정) (대사이상지방간염 (MASH) 치료제 DD01의 제2상 미국 FDA 임상시험 계획 승인)
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from a Korean company (D&D Pharmatech) regarding the approval of a Phase 2 clinical trial by the US FDA. It follows the standard format for 'Major Management Matters' (투자판단 관련 주요경영사항) in the Korean stock market (KIND system). Since it details a specific regulatory event (clinical trial approval) and does not fit into categories like financial reports, dividends, or director dealings, it is classified as a general regulatory filing.
2024-06-10 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the acquisition of shares by 'Rebright Holdings' in 'D&D Pharmatech' following a new listing. This type of filing is specifically categorized as a Major Shareholding Notification (MRQ) in the provided schema.
2024-05-10 Korean
투자판단관련주요경영사항(임상시험계획승인신청) (대사이상지방간염 (MASH) 치료제 DD01의 제2상 미국 FDA 임상시험 계획 승인신청)
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from D&D Pharmatech regarding the submission of a Phase 2 clinical trial application for their drug DD01 to the US FDA. It is a formal disclosure of a material business event (major management matter) related to clinical trial progress. Since it does not fit into specific categories like M&A, dividends, or director dealings, and is a direct regulatory disclosure of a material event rather than a report publication announcement, it falls under the 'Regulatory Filings' category.
2024-05-09 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.